SM16, an Orally Active TGF-β Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury ModelKai Fu, Leona Ling|Arteriosclerosis Thrombosis and Vascular Biology|2008Cited by 84